Jacobio Pharmaceuticals

Trials

Studies that name Jacobio Pharmaceuticals as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:24 UTC. Open this list on ClinicalTrials.gov

• Ph1/Ph2
  NCT07640295 · Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations

  Jacobio Pharmaceuticals Co., Ltd. · recruiting · Metastatic Pancreatic Ductal Adenocarcinoma · study director
• Ph1
  NCT06838338 · JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC

  Jian Li · active not recruiting · Colorectal Cancer · study director
• Ph1/Ph2
  NCT04686682 · A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors

  Jacobio Pharmaceuticals Co., Ltd. · recruiting · NSCLC, SCLC, CRPC · study director
• Ph1
  NCT04587479 · A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors

  Jacobio Pharmaceuticals Co., Ltd. · completed · Solid Tumors, Adult · study director
• Ph1
  NCT04045496 · A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors

  Jacobio Pharmaceuticals Co., Ltd. · completed · Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma · study director
• Ph1
  NCT03518554 · A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors

  Jacobio Pharmaceuticals Co., Ltd. · completed · Non-small Cell Lung Cancer, Head and Neck Cancer, Esophageal Cancer · study director

Grants

NIH projects from RePORTER, fetched 2026-11-12 12:24 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.